HELX Franklin Genomic Advancements ETF

This is an actively managed fund that seeks capital appreciation. Under normal market conditions, the Fund invests at least 80% of its net assets in equity securities of companies that are relevant to the Fund’s investment theme of genomic advancements. The Fund invests predominantly in common stock. Companies relevant to the Fund’s investment theme of genomic advancements are those that the investment manager believes are substantially focused on and/or are expected to substantially benefit from extending and enhancing the quality of human and other life (e.g., animals) by incorporating technological and scientific developments, improvements and advancements in the field of genomics into their business, such as by offering new products or services that rely on genetic engineering, gene therapy, genome analysis, DNA sequencing, synthesis or instrumentation. These companies may include those that research, develop, produce, manufacture or significantly rely on or enable bionic devices, bio-inspired computing, bioinformatics, molecular medicine and diagnostics, pharmaceuticals and agricultural applications of genomics, and related equipment, techniques and processes.

$32.13  -0.00 (0.00%)
As of 05/20/2022 09:30:00 EST     IEX book   CBOE book

---

ETF Information

---

Sponsor:     Franklin Templeton
Category1:  US Equity
Category2:  Single industry
Category3:  Biotechnology
Morningstar category:  
Leverage factor:  1.00
Inception date:  02/27/2020
Current yield:  0.38%
Historical average yield:  0.19%
Market cap:  $14,458,545
Average volume:  3,512
Fees:     0.5000%
Investment style: Actively managed